Drug updated on 3/28/2024
| Dosage Form | Tablet (oral: 50 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Summary
- Ripretinib (Qinlock) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
- Three systematic reviews/meta-analyses were reviewed to gather information about Qinlock's safety and effectiveness in its indication.
- According to one review, health-related quality of life (HRQoL) remained stable in GIST patients treated with ripretinib despite almost all experiencing at least one adverse event from tyrosine kinase inhibitor therapy; this suggests that side effects may be underestimated by physicians or not fully captured by HRQoL measures.
- A network meta-analysis found ripretinib ranked highest among third-line therapies for progression-free survival, overall survival, and disease control rate in treating GISTs after failure of first- and second-line treatments like imatinib and sunitinb; however nilotnib and pimitespib showed better tolerability than ripretininb.
- Another Bayesian network meta-analysis compared renal impairment risks across different tyrosine kinase inhibitors used in cancer treatment: it identified nintedanab and ripretininb as having the lowest risk profiles for renal toxicity among these drugs.
- Despite their efficacy against GISTs, clinicians should consider potential kidney damage when prescribing TKIs such as Qinlock due to differences between individual drugs' targets mechanisms which can lead to varying levels of nephrotoxicity according to a study on incidence rates amongst various TKI medications used on tumour patients.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Qinlock (ripretinib) Prescribing Information. | 2021 | Deciphera Pharmaceuticals, Waltham, MA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| NCCN guidelines insights: gastrointestinal stromal tumors, version 2.2022. | 2022 | Official Journal of the National Comprehensive Cancer Network |
| Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. | 2021 | Annals of Oncology |